Pfizer (PFE) Earnings Date & Reports

Key Takeaways

• Pfizer is scheduled to report third-quarter 2026 results before the market opens on Tuesday, November 3, 2026.
• Wall Street consensus points to adjusted EPS (earnings per share) of roughly $0.75 and revenue near $15.9 billion, implying a modest year-over-year revenue decline.
• The company enters the print with momentum, having beaten expectations in Q2 2026 with $15.03 billion in revenue and $0.77 in adjusted EPS.
• Full-year 2026 guidance stands at $60.5 billion to $62.5 billion in revenue and $2.80 to $3.00 in adjusted diluted EPS.
• Investors will focus on Prevnar vaccine trends, COVID-19 product demand, and pipeline catalysts in obesity and oncology.

Earnings Context and Why It Matters

Pfizer's third-quarter report lands at a pivotal moment for the drugmaker's multi-year turnaround. After a painful post-pandemic reset, management has leaned on cost discipline, acquired products, and a maturing pipeline to rebuild credibility with investors. The Q2 2026 print reinforced that narrative: revenue and adjusted EPS both came in ahead of expectations, prompting the company to raise the midpoint of its full-year revenue guidance. As a result, the upcoming report serves as a referendum on whether that momentum can be sustained. With the stock trading near 52-week highs, investors are watching closely to see whether underlying business strength—beyond volatile COVID-19 products—can justify recent gains.

Earnings Expectations

Analysts expect Pfizer to post adjusted EPS of approximately $0.75 on revenue of roughly $15.9 billion for the third quarter of 2026, according to consensus estimates tracked by Visible Alpha. That revenue figure would represent a decline from the $16.65 billion reported in the year-ago quarter, reflecting the continued drag from shrinking COVID-19 product sales. Guggenheim, which reiterated a Buy rating and $31.00 price target ahead of the release, is more optimistic, modeling revenue of $16.16 billion and EPS of $0.77—above consensus—citing stronger assumptions for Eliquis and COVID-related products.

Management's full-year 2026 guidance frames the quarter. The company expects $60.5 billion to $62.5 billion in revenue and $2.80 to $3.00 in adjusted diluted EPS. The third quarter is also expected to absorb a roughly $650 million acquired in-process research and development (IPR&D) charge tied to an Innovent licensing agreement, a factor analysts are weighing against headline earnings.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. For investors following names like Pfizer and its pharmaceutical peers ahead of earnings, the screener offers a faster way to surface trade ideas, trending stocks, breakout candidates, and emerging market opportunities than manual screening. Explore the AI Screener to build a data-driven watchlist around the next earnings catalyst.

Market Reaction and Investor Sentiment

Sentiment heading into the report is cautiously optimistic. Pfizer shares have climbed more than 20% year-to-date and are trading near their 52-week high, a sign that investors have begun rewarding the company's execution and pipeline progress. Historically, Pfizer has a strong record of beating consensus, exceeding adjusted EPS expectations in each of its last several quarters, with modest post-earnings moves. Still, the stock's elevated positioning raises the bar: a revenue miss, weaker-than-expected Prevnar trends, or disappointing commentary on COVID-19 product demand could trigger profit-taking. Conversely, a beat paired with reaffirmed or raised guidance would likely reinforce the turnaround thesis.

Forward Outlook and Key Factors to Monitor

Beyond the headline numbers, several themes will shape the post-earnings narrative. First, watch the Prevnar franchise. Pfizer has flagged lower birth rates, declining childhood vaccination rates, and potential shifts in government vaccine policy as headwinds, making franchise trajectory a key test of the portfolio's durability.

Second, COVID-19 products remain a swing factor. Management has guided to roughly $4 billion in COVID-related revenue for the year, and investors will assess whether Comirnaty and Paxlovid demand is stabilizing as expected.

Third, the pipeline is central to the long-term story. Attention will center on upcoming readouts, including Phase 3 data for mevrometostat in prostate cancer and additional data in the obesity franchise built around the Metsera acquisition, where Pfizer is advancing weekly and monthly GLP-1 (glucagon-like peptide-1) candidates.

Finally, cost discipline remains a quiet tailwind. Management has expanded its restructuring and productivity savings targets, and investors will look for confirmation that these programs are supporting margins even as the company funds an aggressive late-stage clinical pipeline. Together, these factors will determine whether Pfizer can convert a strong year into durable, multi-year growth.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations